SEC Form 4	
------------	--

 \square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	ROVAL
OMB Number:	3235-0287
Estimated average	burden

Estimated average burden	
hours per response:	0.5

1. Name and Address of Reporting Person* Sachdev Amit (Last) (First) (Middle)			2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [VRTX]		tionship of Reporting Persor : all applicable) Director Officer (give title below)	n(s) to Issuer 10% Owner Other (specify below)
C/O VERTEX PHARMACEUTICALS INCORPORATED		,	3. Date of Earliest Transaction (Month/Day/Year) 06/29/2018		EVP, CRO	
50 NORTHERN	AVENUE		4. If Amendment, Date of Original Filed (Month/Day/Year)	Line)	ridual or Joint/Group Filing (
(Street) BOSTON	MA	02210		X	Form filed by One Reporti Form filed by More than C Person	•
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	06/29/2018		М		1,941	A	\$86.52	48,603	D	
Common Stock	06/29/2018		М		2,155	A	\$91.05	50,758	D	
Common Stock	06/29/2018		S ⁽¹⁾		1,941	D	\$165	48,817	D	
Common Stock	06/29/2018		S ⁽¹⁾		2,155	D	\$170	46,662	D	
Common Stock								882	Ι	401(k)
Common Stock								12,215	I	Held in Trust

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$86.52	06/29/2018		М			1,941	(2)	02/02/2027	Common Stock	1,941	\$0.00	21,358	D	
Stock Option (Right to Buy)	\$91.05	06/29/2018		М			2,155	(3)	02/01/2026	Common Stock	2,155	\$0.00	15,086	D	

Explanation of Responses:

1. Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.

2. The option vests in 16 quarterly installments from 2/3/2017.

3. The option vests in 16 quarterly installments from 2/2/2016.

Remarks:

<u>/s/ Stephen Migausky,</u>

Attorney-in-Fact

07/03/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.